Samir Saleem was named President of BioXcel Therapeutics, Inc. As of November 4, 2026, BioXcel Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 30, 2026, naming 2 appointments (Form 8-K, October 30, 2026).
Sell to companies like BioXcel Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BioXcel Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as BioXcel Therapeutics, Inc. files it.
Also on the record for BioXcel Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Armistice Capital, LLC | 7.05% of the class | 5%+ stakes | Source |
| March 30, 2026 | Stake report, Schedule 13G/A, by Qatar Investment Authority | 0.6% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 8.4% of the class | 5%+ stakes | Source |
| October 1, 2025 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs BioXcel Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on BioXcel Therapeutics, Inc. and the records around it.
BioXcel Therapeutics, Inc. elsewhere on the record
Companies that share a holder
- Qatar Investment Authority also filed stake reports on 9 other companies: Global Business Travel Group, Inc. (Sep 2026), Nanobiotix SA (Jul 2026), West Bay BDC LLC (Jul 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: Fortress Biotech, Inc. (Oct 2026), Karyopharm Therapeutics Inc. (Oct 2026), Once Upon a Farm, PBC (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), Bluejay Diagnostics (Aug 2026)
Watch BioXcel Therapeutics, Inc.
Get an email when BioXcel Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioXcel Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioXcel Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioXcel Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-30 | In | President | 8-K, 2026-10-30 | ||
| 2026-10-30 | In | 8-K, 2026-10-30 |
Who leads BioXcel Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- President: Samir Saleem, appointed (filed 2026-10-30).
New leaders reset buying decisions — get the Full Report on BioXcel Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the President at BioXcel Therapeutics, Inc., with the record behind each one.
Find candidates like President at BioXcel Therapeutics, Inc.Every change, in the filing's words
Appointed: Samir Saleem, President
On October 30, 2026, the Board appointed Samir Saleem, the Company's Chief Restructuring Officer, as President and Secretary of the Company, effective as of 5:00 p.m., Eastern Time, on October 31, 2026, in addition to his continuing service as Chief Restructuring Officer.
Appointed: Samir Saleem
Mr. Saleem will serve as the Company's principal executive officer.
- Dr. Mehta will continue to serve as a member of the Board.
- Commencing November 1, 2026, Dr. Mehta will receive a fee of $5,000 per month for his service as a director until the earliest of his death, resignation, removal or other termination of his service as a director or the dissolution of the Company, consistent with the Company's Non-Employee Director Compensation Program.
Tools for this story
Each opens in a new tab, filled in for BioXcel Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.